MedTrace Logo

Comparative Evaluation of Periglottic Airway Devices With Performed Shape

NCT05639439 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-12-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate four, most popular periglottic airway devices as regards to ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberscope).

Conditions

  • Airway Management

Interventions

DEVICE

Ventilation using the "Fastrach" intubating laryngeal mask airway and glottic view using fibrescope - Group A

Insertion of the intubating laryngeal airway device "Fastrach", evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)

DEVICE

Ventilation using the "Proseal" laryngeal mask airway and glottic view using fibrescope- Group B

Insertion of the laryngeal airway device "Proseal", evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)

DEVICE

Ventilation using the "I-gel" supraglottic airway device and glottic view using fibrescope- Group C

Insertion of the supraglottic airway device "I-gel", evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)

DEVICE

Ventilation using the "Protector" laryngeal airway device and glottic view using fibrescope- Group D

Insertion of the laryngeal airway device "Protector", evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)

Sponsors & Collaborators

  • University Hospital of Patras

    lead OTHER

Principal Investigators

  • Evanthia Dimitriou, MD · University Hospital of Patras

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-04-30
Completion
2024-04-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05639439 on ClinicalTrials.gov